Purpose: This study was designed to evaluate the dosimetric performance of Mobius3D by comparison with an aSi-based electronic portal imaging device (EPID) and Octavius 4D, which are conventionally used for patient-specific prescription dose verification.
Introduction
In the 1990s, the development of linear accelerators and treatment planning, which makes possible three dimentional (3D) dose calculation using computed tomography (CT) images, led to the new radiotherapy method of threedimensional conformal radiotherapy (3DCRT). Since then, various radiotherapy techniques such as intensity modu-lated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), and stereotactic radiosurgery have been developed and have become available for treatment. [1] [2] [3] In particular, VMAT is a radiotherapy in which the treatment device rotates 360° around the patient at high speed while adjusting the radiation rate, gantry speed, and irradiation shape in real time. The method minimizes the amount of radiation distributed around the surrounding normal tis-sues whilst delivering sufficient irradiation to kill cancer cells. 4) Complex and sophisticated treatment techniques also increase the possibility of errors in patient treatment and treatment planning compared with the conventional 3DCRT, thus requiring a precise and strict quality assurance program. 5) The quality assurance program should be implemented efficiently and effectively. In addition, patient-specific prescription dose verification should be performed to verify that the radiation is delivered according to the treatment plan. The TASK GROUP 120 of the American Association of Physicists in Medicine sets out the measurement procedures and dose criteria for various tools used for the verification of patient-specific prescribed doses from IMRT. The report addresses the need for relative dose measurements in a given area or volume, as well as point dose measurements, for patient-specific prescription dose verification. 6) For example, many researchers have investigated and reported on two dimentional (2D) and 3D dose analysis using 2D array detectors, electronic portal imaging devices (EPIDs), gels, and films. [7] [8] [9] [10] Recently, Mobius3D (developed by Mobius Medical Systems, Houston, TX, USA), which can verify a patientspecific prescribed dose by a treatment log-file-based method rather than a phantom-based method, has been used commercially. This dosimetry system can verify treatment plans as well as the prescribed dose using a 3D dose calculation algorithm independent of the treatment logfile. 11) The main advantage of this dosimetry system is that a user does not have to consider the setup errors involved in the installation of a dosimetry device and is not subject to the temporal and spatial constraints of a physical dosimetry device. Therefore, this study was designed to evaluate the dosimetric performance of Mobius3D by comparison with the QA results of an aSi-based EPID (aS1200; Varian Medical Systems, Palo Alto, CA, USA) and Octavius 4D (PTW Freiburg GmbH, Freiburg, Germany), which are conventionally used for patient-specific prescription dose verification. The study was conducted using nine patients, who were treated by volumetric modulated arc therapy.
Materials and Methods

Patient-specific quality assurance system
The patient-specific prescription dose verification systems used in this study to verify the treatment plan of VMAT therapy were Mobius3D, EPID, and Octavius 4D. Mobius3D's independence as a secondary system to confirm treatment plans. Therefore, in this study, the application of user beam data to the Mobius3D system has been minimized, following the recommendations of the manufacturer. The aSi-based EPID used in this study has an ar- To verify the prescribed dose of the calculated treatment plan, a dose verification method for each patient-specific prescription dose verification system was implemented. To examine inter-fraction variation, five fractions were randomly selected during the entire treatment period to verify the prescription dose.
MVP dose comparison and gamma evaluation
To researchers using various phantoms and ion chambers. [13] [14] [15] [16] In a study by McDonald et al. 16) , which used the same Mobius MVP, an ion chamber with a volume of 0.053 cm 3 was used. This chamber represents an intermediate volume between the volumes of the ion chambers used in this study, and the reported results are better than those of this study. The volume-averaging effect of the ion chamber was considered to be maximized in that case, and the results of this study agree with those reported by other researchers within 2%, on average. We applied the 3%/3 mm and 95% pass rate condition, which are commonly applied criteria to the gamma index analysis. It was shown that the results from all three prescription dose verification tools satisfied the criteria.
Results
MVP dose comparison
Gamma evaluation
However, as the criteria were made stricter, the cases satisfying the 95% pass rate criteria were considerably reduced, particularly in the case of Octavius 4D where the mean pass rates decreased rapidly (Fig. 3 ). In addition, the mean standard deviations of the three patient-specific prescription dose verification tools tended to decrease gradually in the order of Octavius 4D, EPID, and Mobius3D.
When the gamma criteria were 2%/2 mm, 2%/3 mm, 3%/2 mm, and 3%/3 mm, the relative percentage dose dif- 
Discussion
In this study, the feasibility of Mobius3D as a patientspecific prescription dose verification tool was evaluated.
Plan 8 showed a large difference of 4.8% between the two ion chambers' measurement values, and the difference between the calculated and the measured values was also large compared with other plans. However, the difference between the value measured by the PTW31010 ion chamber for Plan 8 and the value calculated by the CC dose calculation algorithm was within 0.5%, indicating reasonable consistency. When measuring the dose using the ion chamber, it is important to properly select the location of the ion chamber. In most cases, when the ion chamber is located in an area with severe dose gradients, the dose error between the treatment plan results and the measurement results tends to be large. In the case of Plan 8, the ion chamber was located in a region of severe dose gradient, which is thought to have caused the large difference between the calculated and measured values.
The volume-averaging effect corresponding to the size of the ion chamber should be considered for more accurate dose evaluation. An ion chamber with a small volume, such as the PTW31014, has a small output signal and a large signal-to-noise ratio, which may be a key factor affecting the dose error in the measurement of the absolute dose. However, the PTW31010 ion chamber, which has a larger volume than the PTW31014, had a large output signal, which can more accurately measure the dose. the acceptance criteria of 3%/3 mm, and it was evaluated to be the independent dose verification method.
Phantom-based patient-specific quality assurance is usually performed once before treatment; however, this cannot detect changes and dose delivery errors that occur throughout the entire process of the treatment. Therefore, it is suggested that real-time dose verification is required when treating patients. 18) However, Mobius3D is based on the treatment log-file, meaning it can be used as a simple and convenient tool to conduct quality assurance for each treatment without the time and space constraints of physical devices. As such, it is judged to be a suitable tool for prescription dose verification when the patient conditions are checked and adaptive radiotherapy is performed according to the change in conditions.
Conclusions
In this study, the feasibility of the Mobius3D dosimetry system, which has been used recently as a secondary tool for verifying prescribed dose, was examined. The calculation accuracy of the point dose using Mobius3D showed good agreement with the measured value within 2% on average. In addition, the Mobius3D result of gamma index analysis considering all criteria applied in this study showed consistent results with those obtained by EPID within 0.46%±0.34% on average and within 3.14%±2.85%
for Octavius 4D. Therefore, we conclude that Mobius3D
can be used interchangeably with phantom-based dosimetry systems, which are commonly used as patient-specific prescription dose verification tools, especially under the criteria of 3%/3 mm and 95% pass rate.
